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An Unusual Bacterium
Causing a Brain Abscess
To the Editor: Intracranial abscesses are an
important cause of illness and death in a
neurologic/neurosurgical unit. Early presump-
tive clinical diagnosis supported by radiologic
evidence (computerized axial tomography [CAT]
scan and magnetic resonance imaging) is the
mainstay of diagnosis (1). Abscess contents are
aspirated under stereotaxic guidance and
cultured to isolate causative organisms and
determine their antibiotic sensitivities. Organ-
isms isolated from brain abscesses are usually
streptococci, anaerobic and facultative gram-
negative bacilli, staphylococci, or pseudomonads
(2).
A 24-year-old male farmer came to us with
progressive headache, dizziness, and a low-
grade fever of 2 weeks’ duration. He had had a
pimple on his right cheek approximately 3
weeks before, which had discharged “bluish”
pus on forcible evacuation and subsequently
healed without treatment. No focal neurologic
signs were detected on physical examination.
Because an intracranial space-occupying lesion
was suspected, a lumbar puncture was with-
held. Later, a CAT scan of the patient’s head
revealed a right-sided temporoparietal space-
occupying lesion approximately 3 cm in diam-
eter, suggestive of a unilocular brain abscess.
The abscess was needle aspirated under stereo-
taxic guidance, and the pus was cultured
aerobically and anaerobically. After 24 hours of
aerobic incubation on MacConkey agar at 37°C,
a pure growth of violet-colored colonies appeared,
identified as Chromobacterium violaceum by
the 20E API system (Biomerieux, France).
Other initial laboratory findings were as
follows: blood leukocyte count, 16,200 cells/µL
(84% neutrophils, 15% lymphocytes, 1% eosino-
phils); erythrocyte sedimentation rate
(Westergren method), 22 mm/hour; C-reactive
protein concentration, 96 mg/L; and fasting
blood sugar concentration, 5.1 mmol/L. Blood
urea and C-reactive protein concentrations
after 3 weeks of antibiotic treatment were 4.6
mmol/L and <6 mg/L, respectively.
The organism was sensitive to imipenem
and ciprofloxacin and resistant to cefotaxime
and ceftriaxone, by the Stokes comparative
disk-diffusion antibiotic sensitivity testing
method (3). Ciprofloxacin (as lactate) was
administered intravenously, 400 mg twice a
day, for 4 weeks. Repeated CAT scans, clinical
symptoms, and serial C-reactive protein levels
indicated rapid regression of the abscess
followed by complete cure.
C. violaceum is a gram-negative bacillus
present in soil and aquatic environments of
tropical and subtropical countries or regions
such as Trinidad, Guyana, India, Malaysia,
Florida, and South Carolina. It is a bacterium of
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infections and disseminated disease involving
multiple organs in immunocompromised
patients. In such cases the disease can mimic
septicemic melioidosis (4,5).
In this previously healthy patient, infection
probably originated from the facial abscess. The
patient was negative for HIV antibody
(Serodia), had no history of diabetes mellitus or
other compromising illnesses, and had no
evidence of immunodeficiency. In a previous
case of disseminated C. violaceum infection in a
young patient, postmortem findings revealed
numerous cortical infarcts and hemorrhages (6).
Our isolate from a brain abscess is yet another
case of a relatively avirulent saprophytic
microorganism resulting in a deep-seated
infection in a well-nourished, previously
healthy person.
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First Glycopeptide-Resistant
Enterococcus faecium Isolate from
Blood Culture in Ankara, Turkey
To the Editor: Glycopeptide-resistant entero-
cocci infections are a major problem in hospi-
tals. Infection or colonization by vancomycin-
resistant enterococci was first reported in
France (1) and the United Kingdom (2); since
then, these organisms have been reported
throughout the world. In Turkey, vancomycin
and teicoplanin have been used to treat serious
methicillin-resistant Staphylococcus aureus and
ampicillin-resistant enterococci infections.
We describe the case of an acute myelocytic
leukemia patient with vancomycin-resistant
enterococci bloodstream infection. This is the
first glycopeptide-resistant Enterococcus
faecium isolate from our hospital and from
Ankara, Turkey. The patient had not been
cared for at another institution.
A 68-year-old man, hospitalized with acute
myelocytic leukemia, had fever episodes during
the neutropenia following three courses of
remission-induction chemotherapy
(daunorubicin+cytosine arabinoside). A combi-
nation of antibiotics including vancomycin,
ceftazidime (sometimes imipenem), and
amikacin was administered with different
regimens during the 5 months of hospitaliza-
tion. Blood, urine, and rectal swab cultures
during this period were positive for different
Enterobacteriaceae spp. but always negative for
vancomycin-resistant enterococci. For long-term
hospitalizations, our center routinely performs
surveillance rectal swab cultures. At the end of
month 5, E. faecium was isolated from the blood
cultures, just 1 day before the patient’s death.
The strain was identified by conventional
methods, commercial automatic systems (API
Strep-Biomerièux, France), and polymerase
chain reaction. Susceptibility patterns showed
that the isolate was resistant to all antibiotics
except ciprofloxacin and levofloxacin. When the
E-test was used, MIC levels for vancomycin,
teicoplanin, ciprofloxacin, and levofloxacin were
256 µg/mL, 64 µg/mL, 0.75 µg/mL, and 1.5 µg/
mL, respectively. VAN-A1 and Van-A2 type
resistance genes were detected by polymerase
chain reaction. Hacettepe University microbiol-
ogy laboratories confirmed these results (3,4).
After this strain was isolated, 1,266 stool
and 176 rectal swab samples were taken from
hospital personnel in three sessions >1 week
apart, and patients were tested for vancomycin-
resistant enterococci. Swab cultures from all
environmental surfaces (bed rails, bedside
commodes, carts, charts, doorknobs, faucet
handles) were also examined. We injected all
samples with 5% sheep blood agar with vanco-
mycin (6 mg/L); vancomycin-resistant E. faecium
was not identified in any sample.